Consensus HUTCHMED (China) Limited Nasdaq

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2024 BST			5-day change	1st Jan Change
18.92 ^USD	+0.21%		+1.39%	+4.47%

06-03	HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine	CI
05-24	HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology	CI

6925f.pEAxHIcHUMdhPyNZ4UR_JUt2h0UB6DvDGQ5upQYdGhc.6iN6WdNtaPcUcFc8sRY5dz4H0Xd3oUGQVlQXiFNOe033FnxR4FUXkBlueg~783c58ab81f35d5850e81911b83d014a

Deutsche Bank Upgrades HUTCHMED to Buy From Hold, Adjusts Price Target to $22.10 From $20	11-24	MT
Goldman Sachs Adjusts Price Target on HUTCHMED (China) to $17 From $15, Maintains Neutral Rating	11-10	MT
Hutchmed Says Platelet Disorder Drug Increased Durable Response Rate in Phase 3 Trial	21/08/23	MT
Goldman Sachs Adjusts HUTCHMED (China)'s Price Target to $16 From $14, Maintains Neutral Rating	09/08/22	MT
AstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate	08/08/22	MT
AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Trial	08/08/22	MT
Hutchmed Says Phase 2 Study to Treat Patients With MET-Driven Non-Small Lung Cancer Shows Improved Response Rates	13/07/22	MT
Deutsche Bank Downgrades HUTCHMED to Hold From Buy, Adjusts Price Target to $20 From $37	05/05/22	MT
HUTCHMED CHINA : Goldman Sachs Downgrades Hutchison China MediTech to Neutral From Buy	22/09/21	MT
HUTCHMED CHINA : Jefferies Initiates Hutchison China MediTech at Buy Rating With $52 Price Target	03/08/21	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.715 USD

Average target price

5.719 USD

Spread / Average Target

+53.92%

High Price Target

8.006 USD

Spread / Highest target

+115.49%

Low Price Target

2.766 USD

Spread / Lowest Target

-25.55%

Trading Rating

Investor Rating

ESG Refinitiv